MedTrace Logo

Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

NCT07687433 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-07-07

No results posted yet for this study

Summary

To observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal cancer with sphincter-preservation demand.

Conditions

  • Rectal Cancer Patients

Interventions

DRUG

Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib

Long-course concurrent chemoradiotherapy regimen: 45-50 Gy administered in 25 fractions, with concurrent capecitabine 1650 mg/m²/day, bid on days 1-14, every 3 weeks as one cycle. Adebrelimab: 1200 mg, intravenous infusion, on D1, once every 3 weeks. Apatinib: 250 mg, orally, 5 days on and 2 days off; if the patient cannot tolerate the toxicity, the dose may be reduced to 125 mg once daily. Each cycle is 21 days, with a total of 6 cycles of neoadjuvant therapy before surgery. Efficacy evaluation is performed after every 2 cycles. After 6 cycles of long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib, the research team will reassess the patient. For resectable patients, surgery will be performed 4-6 weeks after neoadjuvant therapy. For patients who decline surgery or are deemed unfit for surgery after 6 cycles, if the investigator believes that continued treatment with Adebrelimab and Apatinib may still provide benefit, the treatment may be continued until

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-29
Primary Completion
2028-05-29
Completion
2029-05-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07687433 on ClinicalTrials.gov